Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Price Target from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given an average rating of “Hold” by the five analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $4.50.

A number of equities research analysts recently issued reports on HRTX shares. Needham & Company LLC lowered their target price on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wall Street Zen cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC increased its stake in Heron Therapeutics by 23.4% during the second quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 5,953 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of Heron Therapeutics by 6.7% in the 2nd quarter. Palumbo Wealth Management LLC now owns 132,433 shares of the biotechnology company’s stock valued at $274,000 after buying an additional 8,330 shares during the period. Richmond Brothers Inc. grew its position in shares of Heron Therapeutics by 1.8% during the 2nd quarter. Richmond Brothers Inc. now owns 554,469 shares of the biotechnology company’s stock valued at $1,148,000 after buying an additional 9,568 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Heron Therapeutics by 5.1% during the second quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 11,716 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the second quarter worth about $26,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Trading Down 0.9%

Heron Therapeutics stock opened at $1.15 on Friday. The stock has a fifty day moving average price of $1.20 and a 200 day moving average price of $1.56. Heron Therapeutics has a 52 week low of $1.00 and a 52 week high of $2.68. The firm has a market capitalization of $210.87 million, a P/E ratio of -57.50 and a beta of 1.30.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The business had revenue of $38.21 million during the quarter, compared to analysts’ expectations of $39.03 million. Heron Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Heron Therapeutics will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.